ImmuPharma and Cephalon had signed an option agreement in 2008,when the ImmuPharma designed and funded Phase IIb study was ongoing.
ImmuPharma was paid $15m by Cephalon before the results of the phase IIb study for the exclusive option to enter into the worldwide license.
Following positive results of the ImmuPharma phase IIb study in early 2009, Cephalon exercised its option by paying a further $30m for an exclusive worldwide license, which was a part of an agreement worth $500m.
Cephalon took over the responsibilities and costs for the development and commercialisation of Lupuzor, after the completion of the license agreement.